On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the Board") of AnaptysBio, Inc. (the Company") that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023. Dr. Topper's resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. Dr. Topper has served on the Company's Board of
Directors since 2007 and as Chairman since 2015. During this tenure, he has overseen the evolution of the Company from an early-stage antibody generation platform to a clinical-stage organization. Following Dr. Topper's resignation from the Board, the Company entered into an Advisory Agreement with him, through which he will remain in a transitionary role as an advisor to the Board through First Quarter 2024. On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
ANAPTYSBIO, INC. 
